In addition, our previous study of Triagonist in SH-SY5Y cells has shown that each receptor (GLP-1R, GIPR, and GcgR) contributed to the drug’s demonstrated neuroprotective effects [7], further emphasizing the possible advantages of multi-agonism over single GLP-1R agonism in the treatment of various neurological disorders. This evidence concerns the gene GLP1R and nervous system disorder.